vs
APOGEE ENTERPRISES, INC.（APOG）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是APOGEE ENTERPRISES, INC.的1.5倍（$540.7M vs $351.4M），APOGEE ENTERPRISES, INC.净利率更高（4.7% vs -2.9%，领先7.6%），APOGEE ENTERPRISES, INC.同比增速更快（1.6% vs -14.1%），过去两年APOGEE ENTERPRISES, INC.的营收复合增速更高（2.9% vs -2.3%）
Apogee Enterprises是一家美国音频设备制造商，主营音频接口、模数与数模转换器、USB及iOS麦克风，同时还开发音频制作相关软件，产品广泛服务于专业录音、音乐创作等音频领域，在全球音频行业拥有较高的认可度。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
APOG vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.5倍
$351.4M
营收增速更快
APOG
高出15.7%
-14.1%
净利率更高
APOG
高出7.6%
-2.9%
两年增速更快
APOG
近两年复合增速
-2.3%
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $351.4M | $540.7M |
| 净利润 | $16.6M | $-15.7M |
| 毛利率 | 22.4% | 37.5% |
| 营业利润率 | 7.3% | 1.0% |
| 净利率 | 4.7% | -2.9% |
| 营收同比 | 1.6% | -14.1% |
| 净利润同比 | 568.8% | 34.0% |
| 每股收益（稀释后） | $0.78 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APOGICUI
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | $540.7M | ||
| Q3 25 | $358.2M | $537.0M | ||
| Q2 25 | $346.6M | $548.9M | ||
| Q1 25 | $345.7M | $604.7M | ||
| Q4 24 | $341.3M | $629.8M | ||
| Q3 24 | $342.4M | $589.1M | ||
| Q2 24 | $331.5M | $596.5M |
净利润APOGICUI
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | $-15.7M | ||
| Q3 25 | $23.6M | $-3.4M | ||
| Q2 25 | $-2.7M | $35.3M | ||
| Q1 25 | $2.5M | $-15.5M | ||
| Q4 24 | $21.0M | $-23.8M | ||
| Q3 24 | $30.6M | $-33.0M | ||
| Q2 24 | $31.0M | $-21.4M |
毛利率APOGICUI
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 37.5% | ||
| Q3 25 | 23.1% | 37.4% | ||
| Q2 25 | 21.7% | 37.9% | ||
| Q1 25 | 21.6% | 34.7% | ||
| Q4 24 | 26.1% | 36.1% | ||
| Q3 24 | 28.4% | 34.8% | ||
| Q2 24 | 29.8% | 34.8% |
营业利润率APOGICUI
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | 1.0% | ||
| Q3 25 | 7.5% | 2.6% | ||
| Q2 25 | 2.0% | 1.9% | ||
| Q1 25 | 1.8% | 2.1% | ||
| Q4 24 | 8.4% | 6.0% | ||
| Q3 24 | 12.3% | 1.4% | ||
| Q2 24 | 12.5% | 1.3% |
净利率APOGICUI
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | -2.9% | ||
| Q3 25 | 6.6% | -0.6% | ||
| Q2 25 | -0.8% | 6.4% | ||
| Q1 25 | 0.7% | -2.6% | ||
| Q4 24 | 6.1% | -3.8% | ||
| Q3 24 | 8.9% | -5.6% | ||
| Q2 24 | 9.4% | -3.6% |
每股收益（稀释后）APOGICUI
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | $-0.63 | ||
| Q3 25 | $1.10 | $-0.14 | ||
| Q2 25 | $-0.13 | $1.43 | ||
| Q1 25 | $0.12 | $-0.63 | ||
| Q4 24 | $0.96 | $-0.97 | ||
| Q3 24 | $1.40 | $-1.35 | ||
| Q2 24 | $1.41 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.5M | — |
| 总债务越低越好 | $232.3M | — |
| 股东权益账面价值 | $511.8M | $2.1B |
| 总资产 | $1.1B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资APOGICUI
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | — | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $32.8M | — | ||
| Q1 25 | $41.4M | — | ||
| Q4 24 | $43.9M | $308.6M | ||
| Q3 24 | $51.0M | $312.5M | ||
| Q2 24 | $30.4M | $302.6M |
总债务APOGICUI
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $285.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APOGICUI
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | $2.1B | ||
| Q3 25 | $500.2M | $2.1B | ||
| Q2 25 | $481.8M | $2.1B | ||
| Q1 25 | $487.9M | $2.0B | ||
| Q4 24 | $522.1M | $2.0B | ||
| Q3 24 | $506.4M | $2.0B | ||
| Q2 24 | $480.0M | $2.0B |
总资产APOGICUI
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $4.1B | ||
| Q3 25 | $1.2B | $4.1B | ||
| Q2 25 | $1.2B | $4.1B | ||
| Q1 25 | $1.2B | $4.2B | ||
| Q4 24 | $1.2B | $4.2B | ||
| Q3 24 | $917.1M | $4.3B | ||
| Q2 24 | $889.0M | $4.3B |
负债/权益比APOGICUI
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $122.5M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | 7.8% | 4.6% |
| 现金转化率经营现金流/净利润 | 7.37× | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流APOGICUI
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $60.6M | ||
| Q3 25 | $57.1M | $56.7M | ||
| Q2 25 | $-19.8M | $11.2M | ||
| Q1 25 | $30.0M | $51.3M | ||
| Q4 24 | $31.0M | $40.2M | ||
| Q3 24 | $58.7M | $36.1M | ||
| Q2 24 | $5.5M | $82.0M |
自由现金流APOGICUI
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $36.0M | ||
| Q3 25 | $52.4M | $27.6M | ||
| Q2 25 | $-26.9M | $-8.5M | ||
| Q1 25 | $19.1M | $36.7M | ||
| Q4 24 | $22.0M | $16.1M | ||
| Q3 24 | $50.2M | $16.2M | ||
| Q2 24 | $-1.8M | $62.5M |
自由现金流率APOGICUI
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 6.6% | ||
| Q3 25 | 14.6% | 5.1% | ||
| Q2 25 | -7.8% | -1.5% | ||
| Q1 25 | 5.5% | 6.1% | ||
| Q4 24 | 6.4% | 2.6% | ||
| Q3 24 | 14.7% | 2.7% | ||
| Q2 24 | -0.5% | 10.5% |
资本支出强度APOGICUI
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 4.6% | ||
| Q3 25 | 1.3% | 5.4% | ||
| Q2 25 | 2.1% | 3.6% | ||
| Q1 25 | 3.2% | 2.4% | ||
| Q4 24 | 2.6% | 3.8% | ||
| Q3 24 | 2.5% | 3.4% | ||
| Q2 24 | 2.2% | 3.3% |
现金转化率APOGICUI
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | 12.08× | — | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
